Mizuho lifts target for ResMed stock to USD 240.00

Published on 10/20/2026 at 19:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed will report first-quarter fiscal 2027 results on October 29, 2026. ResMed stock costs EUR 219.05 on October 20, 2026 before results.

Analyst target and reporting date

Mizuho raised its ResMed target from USD 235.00 to USD 240.00 on October 13, 2026.
ResMed plans to publish first-quarter fiscal 2027 results on October 29, 2026.
ResMed stock costs EUR 219.05 at Lang & Schwarz on October 20, 2026 at 7:20 p.m. CEST.

Isometrische 3D-Illustration von Labor, Fertigungslinie und Versand medizinischer Geräte — ResMed Inc. (ISIN US7611521078): isometrische 3D-Darstellung zeigt die komplette Wertschöpfungskette von Atemtherapiegeräten und Versand, Illustration mit AI erstellt.

ResMed Inc. (ISIN US7611521078) is heading into its October 29 results date after Mizuho raised its price target from USD 235.00 to USD 240.00 on October 13, 2026. According to Markets Insider, analyst Anthony Petrone retained an Outperform rating while citing procedure-volume headwinds linked to health-care policy changes. ResMed will publish first-quarter fiscal 2027 results on October 29, 2026, according to its ResMed release dated October 1, 2026. ResMed was trading at EUR 219.05 at Lang & Schwarz on October 20, 2026 at 7:20 p.m. CEST.

Target reaches USD 240.00

Mizuho's move is the most recent named analyst action in the available coverage. The new USD 240.00 target compares with the prior USD 235.00 target, an increase of 2.13 percent. The report also kept an Outperform rating, but identified potential procedure-volume pressure from changes affecting the Affordable Care Act and Medicaid.

How far is the stock from its range?

On the NYSE, ResMed last traded at USD 245.74 on October 20, 2026 at 1:27 p.m. ET. The same market snapshot places the 52-week range at USD 180.27 to USD 277.67, leaving the stock 11.50 percent below its 52-week high in the home-market quotation. ResMed's market capitalization was USD 34.6 billion, while trading volume stood at 567,053 shares.

Valuation and October 29 results

ResMed's price-to-earnings ratio was 23.63 and its trailing dividend yield was 0.01 percent on October 20, 2026. The October 29 report will give investors the next operating checkpoint for the medical-technology company, which serves sleep and respiratory-care markets as well as connected software.

Comparison with peers

ResMed Inc.: price-to-earnings ratio 23.63, market capitalization USD 34.6 billion. DexCom, Inc. (Nasdaq, USD): down 0.36 percent, price-to-earnings ratio 33.89, market capitalization USD 32.3 billion. Align Technology, Inc. (Nasdaq, USD): up 0.04 percent, price-to-earnings ratio 25.87, market capitalization USD 10.6 billion. The comparison places ResMed below both peers on the reported price-to-earnings measure, while its market value is higher than DexCom's and Align Technology's.

ResMed stock before the report

The next dated catalyst is the first-quarter fiscal 2027 release on October 29, 2026, after the NYSE closes. The current euro quotation is an after-hours indication for German investors and is separate from the USD quotation on the NYSE.

ResMed was trading at EUR 219.05 at Lang & Schwarz on October 20, 2026 at 7:20 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of ResMed stock.